Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

D'Alfonso TM, Pareja F, Paula AD, Vahdatinia M, Gazzo A, Ferrando L, et al. Whole-exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. J Pathol Clin Res. 2021;7(2):113-120.

Assarzadegan N, Salimian K, Hutchings D, Windon AL, Voltaggio L, Montgomery EA. Clinicopathological study of blue nevi of the gastrointestinal (GI) tract: first case series. J Clin Pathol. 2021;74(3):167-170.

Patel A, Hoda RS, Hoda SA. Papillary Breast Tumors: Continuing Controversies and Commentary on WHO's 2019 Criteria and Classification. Int J Surg Pathol. 2021:10668969211035843.

Soshnev AA, C Allis D, Cesarman E, Melnick AM. Histone H1 mutations in lymphoma: a link(er) between chromatin organization, developmental reprogramming, and cancer. Cancer Res. 2021.

Rijo MP, Diani-Moore S, Yang C, Zhou P, Rifkind AB. Roles of the ubiquitin ligase CUL4B and ADP-ribosyltransferase TiPARP in TCDD-induced nuclear export and proteasomal degradation of the transcription factor AHR. J Biol Chem. 2021;297(2):100886.

Gaffney C, Liu D, Cooley V, Ma X, Angulo C, Robinson B, et al. Tumor size and genomic risk in localized prostate cancer. Urol Oncol. 2021;39(7):434.e17-434.e22.

Limberg J, Kucher W, Fasano G, Hoda S, Michaels A, Marti JL. Intraductal Papilloma of the Breast: Prevalence of Malignancy and Natural History Under Active Surveillance. Ann Surg Oncol. 2021;28(11):6032-6040.

Sakunrangsit N, Pholtaisong J, Sucharitakul J, Wanna-Udom S, Prombutara P, Pisitkun P, et al. Identification of candidate regulators of mandibular bone loss in FcγRIIB Mice. Sci Rep. 2021;11(1):18726.

Stephens EA, Ludwicki MB, Meksiriporn B, Li M, Ye T, Monticello C, et al. Engineering Single Pan-Specific Ubiquibodies for Targeted Degradation of All Forms of Endogenous ERK Protein Kinase. ACS Synth Biol. 2021;10(9):2396-2408.

Petroni G, Buqué A, Yamazaki T, Bloy N, Di Liberto M, Chen-Kiang S, et al. Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER Breast Cancer. Clin Cancer Res. 2021;27(7):1855-1863.